Failure to Monitor Anticoagulant/Antiplatelet Therapy and Specify Safe Ondansetron Dose
Summary
The facility failed to monitor residents receiving anticoagulant or antiplatelet medications for signs and symptoms of bleeding in accordance with their care plans. Resident 3 was admitted with acute respiratory failure with hypoxia, cachexia, and DM, and had severely impaired cognition. The resident had orders for Aspirin 81 mg daily for CVA prophylaxis and Eliquis 2.5 mg twice daily for CVA prophylaxis. The care plan directed staff to monitor for blood in the urine or stool, unusual bleeding, bleeding from the gums or nose, excessive wound bleeding, large hemorrhagic areas, and petechiae, but the record did not show documented monitoring for these signs. RN 3 stated no monitoring was being done because it was in the care plan, and the DON stated there were no physician orders for monitoring because the facility had removed them after being told monitoring was not needed if it was in the care plan. Resident 40 was admitted with dementia, DM, and atrial fibrillation and had severely impaired cognition. The resident received Eliquis 2.5 mg twice daily for DVT prevention. The care plan required monitoring and documentation of adverse reactions to anticoagulant therapy, including blood in urine or stool, severe headaches, nausea, vomiting, diarrhea, muscle or joint pain, lethargy, bruising, blurred vision, shortness of breath, appetite loss, mental status changes, vital sign changes, bleeding gums, nosebleeds, unusual bruising, lab changes, blood pressure changes, and blood clot. The record did not show documented evidence that staff monitored the resident for these adverse reactions in accordance with the care plan. Resident 75 was admitted and later readmitted with DM and kidney failure and had moderately impaired cognition. The resident had orders for Brillinta 60 mg twice daily for MI and Aspirin delayed release 81 mg for CVA prophylaxis, and received both medications during the review period. The care plan required monitoring for bleeding and bruising related to antiplatelet therapy. During observation, a large dark purple bruise was noted on the left anterior hand, and the resident stated he probably bumped his hand on the doorway. RN 3 stated the bruise had not been reported to the physician because nursing was not aware of the condition and the need to monitor for bruising or bleeding due to antiplatelet use. CNA 5 gave inconsistent statements about when and to whom the bruise had been reported, and the DON stated there was no change of condition or physician notification for the bruises observed three days earlier. The resident record did not document the bruising. The facility also failed to include a maximum daily dose in the physician order for Resident 65’s ondansetron. Resident 65 was admitted with muscle wasting and atrophy and COPD and had severely impaired cognition. The order was for Ondansetron 8 mg every 6 hours as needed for nausea/vomiting for 14 days, but it did not specify the adult maximum dose. RN 1 stated the resident had vomiting and received Ondansetron doses on two occasions, and during review she stated the maximum daily allowance was 24 mg per day and that she would verify the dosage with pharmacy. The order was later clarified to include a limit not to exceed 24 mg in 24 hours, and the DON stated the dosage had exceeded the recommended dosage and was a potential for overdosing.
Penalty
Resources
Below are regulatory guidelines relevant to this citation:
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release July 29, 2026) and official state health department websites — never guesswork.
In your survey window? See what surveyors are citing.
The Survey-Prep Report maps your facility's risk from 12 months of CMS and state citation data — what's being cited around you and what to check first. $129 one-time.